TOP HEADLINES

Featured Story

Recruitment specialist Trialbee snags a deal with AstraZeneca

Trialbee, a Swedish patient-recruitment outfit, has added AstraZeneca to its client roster, bringing its direct-to-patient technology to the U.K. drugmaker.

Quintiles homes in on small biotechs with new service offering

Quintiles, the world's largest CRO, is dialing up its focus on nascent drugmakers, launching a biotech-focused service offering designed to meet the particular needs of the industry's seedlings without losing them in the Big Pharma shuffle.

Evotec signs a Huntington's deal as diabetes project falls through

Risk-sharing researcher Evotec took a blow last week when partner Hyperion Therapeutics pulled the plug on a diabetes trial, but the German company is keeping things moving, expanding an agreement that will put it to work on treatments for Huntington's disease.

Icon and Medidata unite to give patients a louder voice in clinical trials

CRO magnate Icon and and eClinical outfit Medidata are pooling their resources to offer a combined platform for patient-reported outcomes in clinical trials, touting their technology as faster and more effective in surveying participants.

SRI teams up with Japan's Nobelpharma on gynecology drug

Nonprofit researcher SRI International has struck a deal with Japanese drugmaker Nobelpharma to collaborate on a new treatment for the painful gynecological disease endometriosis.

MORE NEWS

From Our Sister Sites

FierceBiotech

In this week's EuroBiotech Report, cash-starved European cancer startups had reason to cheer when Aglaia Biomedical Ventures revealed a new, €65 million ($84 million) oncology fund. The Dutch VC shop plans to invest the cash pool--which could rise to €100 million--in up to 15 early-stage biotechs. And more.

FierceBiotech

An embattled Eli Lilly won a major battle today, gaining the FDA's approval to market dulaglutide for Type 2 diabetes. It will be sold as Trulicity.